228 related articles for article (PubMed ID: 30964987)
21. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
22. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
23. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
24. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
25. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
27. A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Wang J; Liang B; Chen Y; Fuk-Woo Chan J; Yuan S; Ye H; Nie L; Zhou J; Wu Y; Wu M; Huang LS; An J; Warshel A; Yuen KY; Ciechanover A; Huang Z; Xu Y
Eur J Med Chem; 2021 Apr; 215():113267. PubMed ID: 33639344
[TBL] [Abstract][Full Text] [Related]
28. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
29. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
32. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
33. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
[TBL] [Abstract][Full Text] [Related]
34. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Xu Y; Fulciniti M; Samur MK; Ho M; Deng S; Liu L; Wen K; Yu T; Chyra Z; Dereibal S; Zhang L; Yao Y; Chakraborty C; Morelli E; Li N; Lopez MA; Perini T; Mu S; An G; Alonso R; Bianchi G; Tai YT; Anderson KC; Qiu L; Munshi NC
Blood; 2020 Jul; 136(4):468-479. PubMed ID: 32187357
[TBL] [Abstract][Full Text] [Related]
35. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
36. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
37. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
38. Contribution of Inhibition of Protein Catabolism in Myeloma.
Bianchi G; Anderson KC
Cancer J; 2019; 25(1):11-18. PubMed ID: 30694855
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
Oerlemans R; Berkers CR; Assaraf YG; Scheffer GL; Peters GJ; Verbrugge SE; Cloos J; Slootstra J; Meloen RH; Shoemaker RH; Dijkmans BAC; Scheper RJ; Ovaa H; Jansen G
Invest New Drugs; 2018 Oct; 36(5):797-809. PubMed ID: 29442210
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
Acosta-Alvear D; Cho MY; Wild T; Buchholz TJ; Lerner AG; Simakova O; Hahn J; Korde N; Landgren O; Maric I; Choudhary C; Walter P; Weissman JS; Kampmann M
Elife; 2015 Sep; 4():e08153. PubMed ID: 26327694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
